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Abstract
Background
Pediatric Phase I cancer trials are critical for establishing the safety and dosing of anti-can-
cer treatments in children. Their implementation, however, must contend with the rarity of
many pediatric cancers and limits on allowable risk in minors. The aim of this study is to
describe the risk and benefit for pediatric cancer Phase I trials.
Methods and findings
Our protocol was prospectively registered in PROSPERO (CRD42015015961). We system-
atically searched Embase and PubMed for solid and hematological malignancy Phase I
pediatric trials published between 1 January 2004 and 1 March 2015. We included pediatric
cancer Phase I studies, defined as “small sample size, non-randomized, dose escalation
studies that defined the recommended dose for subsequent study of a new drug in each
schedule tested.” We measured risk using grade 3, 4, and 5 (fatal) drug-related adverse
events (AEs) and benefit using objective response rates. When possible, data were meta-
analyzed. We identified 170 studies meeting our eligibility criteria, accounting for 4,604
patients. The pooled overall objective response rate was 10.29% (95% CI 8.33% to
12.25%), and was lower in solid tumors, 3.17% (95% CI 2.62% to 3.72%), compared with
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hematological malignancies, 27.90% (95% CI 20.53% to 35.27%); p < 0.001. The overall
fatal (grade 5) AE rate was 2.09% (95% CI 1.45% to 2.72%). Across the 4,604 evaluated
patients, there were 4,675 grade 3 and 4 drug-related AEs, with an average grade 3/4 AE
rate per person equal to 1.32. Our study had the following limitations: trials included in our
review were heterogeneous (to minimize heterogeneity, we separated types of therapy and
cancer types), and we relied on published data only and encountered challenges with the
quality of reporting.
Conclusions
Our meta-analysis suggests that, on the whole, AE and response rates in pediatric Phase I trials
are similar to those in adult Phase I trials. Our findings provide an empirical basis for the refine-
ment and review of pediatric Phase I trials, and for communication about their risk and benefit.
Author summary
Why was this study done?
• Phase I cancer clinical trials aim to determine the safety of a new drug, and present a
high risk of serious adverse events with limited prospect of therapeutic benefit.
• National and international regulations establish limits on allowable risk for research
involving children.
• Little is known about the level of risk and benefit in pediatric Phase I trials in oncology.
• We designed this systematic review with meta-analysis to establish the risk and benefit
associated with pediatric Phase I studies in oncology, and to compare our results with
those reported for Phase I adult studies in the literature.
What did the researchers do and find?
• We systematically searched for pediatric Phase I cancer studies published between 1 Jan-
uary 2004 and 1 March 2015.
• We identified 170 studies with 4,604 patients meeting eligibility criteria.
• The pooled overall objective response rate was 10.29%, with a response rate of 3.17% for
solid tumors and 27.90% for hematological malignancies.
• The overall rate of clearly reported fatal (grade 5) adverse events was 2.09%.
• The average grade 3/4 adverse event rate per person was equal to 1.32.
What do these findings mean?
• Serious (grade 3, 4, and 5) adverse event and response rates for pediatric Phase I cancer
studies were similar to those reported for adult studies.
Risk and benefit for pediatric Phase 1 Trials in oncology
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• These data help to inform the assessment and ethical evaluation of, and communication
about, risk for pediatric Phase I cancer protocols.
Introduction
Despite enormous strides in treating pediatric malignancies, childhood cancer remains the
fourth leading cause of death in US children aged 1–18 years [1]. Historically, many pediatric
malignancies were treated by adjusting the dosages of anti-cancer drugs that were proven
effective in adults [2,3]. However, many pediatric tumors differ histologically from those of
adults. Also, children’s physiology may substantially change drug pharmacokinetics and phar-
macodynamics [4,5]. As a consequence, new cancer treatments must generally be validated in
pediatric populations.
Phase I trials in oncology aim at establishing dose, safety, and preliminary evidence of effi-
cacy of new cancer drugs. Participants generally have advanced cancer and have exhausted
standard therapeutic options. Because Phase I trials expose patients to unproven drugs and
involve a high degree of uncertainty about risk, the ethical oversight approaches have been
widely debated [6–12]. In pediatric trials, participants cannot legally provide informed con-
sent, thus adding an additional challenge to the conduct and ethical evaluation of protocols
[13–22]. As with adults, Phase I trials in children present risks of serious toxicity and limited
prospect of benefit, and patients are potentially exposed to levels of drug that are inactive
[2,11,23,24]. Longer survival times of children can be associated with possible later side effects
of cancer therapy, including secondary cancers. Several practices are designed to maximize the
therapeutic prospect of Phase I pediatric cancer trials, including prior testing in adults and
testing within a narrower dose range [2,4,25].
Little is known about the risk and benefit for pediatric Phase I trials and how well these tri-
als comport with the ethical expectation that such studies offer a favorable balance of risk and
therapeutic benefit. In 2005, Lee et al. suggested that the proportion of pediatric Phase I mono-
therapy trial participants experiencing drug-related fatalities was 0.5%, and the objective
response rate was 9.6% [26]. Since 2005, major new drug classes have emerged, as have novel
dosing regimens intended to improve risk/benefit balance [11,24,25,27–29]. In what follows,
we used systematic review and meta-analysis to establish the risk/benefit balance for contem-
porary pediatric Phase I cancer studies and to appraise the value of practices aimed at improv-
ing the risk/benefit balance of Phase I studies in oncology.
Methods
Our protocol was prospectively registered in PROSPERO (CRD42015015961) [30]. We fol-
lowed PRISMA guidelines (S1 PRISMA Checklist).
Search strategy
We systematically searched Embase and PubMed for articles and abstracts published between
1 January 2004 and 1 March 2015, using strategies that included key words and suggested
MeSH and Emtree entry terms, their synonyms, and closely related words. Searches were not
limited by language. The starting date of our search period was determined by the timing of
the last study to our knowledge presenting data on the efficiency of pediatric Phase I trials in
oncology [26]. The full search strategies were checked using the Canadian Agency for Drugs
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and Technologies in Health peer-review checklist; our literature search strategies and a flow
diagram are presented in S1 Table and S1 Fig.
Study selection and eligibility criteria
We included pediatric cancer Phase I studies, defined as “small sample size, non-randomized,
dose escalation studies that defined the recommended dose for subsequent study of a new
drug in each schedule tested” [31], as well as Phase I/II reports containing results of Phase I
studies provided separately. We defined “minors” as individuals below the age of 21 years.
Inclusion criteria were as follows: (1) all or most participants (over 50%) were less than 21
years old and the study was indicated as pediatric or results for pediatric participants were
reported separately; (2) any malignancy (e.g., solid or hematological); and (3) assessment of
chemotherapy (cytotoxic drugs) and/or targeted therapy (targeted therapy was defined as
monoclonal antibodies or small molecules or antibody drug conjugates [32]). We excluded
reports for studies involving (1) topical only or regionally delivered drugs (i.e., delivered
directly to the tumor without any systemic effects or minimal systemic effects); (2) only the
pharmacokinetics and/or pharmacodynamics of a tested treatment; (3) nonpharmacological
modalities (e.g., surgery, radiotherapy, gene therapy, stem cell therapy, or any of these com-
bined with pharmacological therapies); or (4) supportive care without anticancer agents or
with other interventions not falling under targeted therapy, chemotherapy, or combined ther-
apy categories (such as antiviral agents or nonspecific immunotherapy). All inclusion and
exclusion criteria were defined prospectively in the protocol [30]. They are also listed in S2
Table.
Data extraction
We created and piloted an extraction form, and on the basis of the pilot we refined the form
and prepared the final version. Data were extracted from each publication independently by 2
reviewers (MW, MMB, MK, RRJ, AW, JP, AS, JWM, KS, MTW). All reviewers received train-
ing prior to extraction. Disagreements were resolved by discussion, and when necessary a
third person, an arbiter, was involved (MMB, DN). An experienced methodologist and experi-
enced experimental oncologist had supervisory roles (MMB, DN). In the case of duplicate pub-
lications for the same study, the results from full publication and, if possible, the most recent
version were used in the extraction. Data were extracted using Google Forms. From each
study, we extracted data related to study design, funding, reason for stopping the trial, patient
characteristics, intervention, outcomes, and the timing of pediatric testing relative to adult
testing. Because Phase I cancer studies do not generally have comparator arms or measure sur-
vival endpoints, we used objective response rate and the number of patients receiving recom-
mended dose as proxies for therapeutic benefit [33–37].
Data synthesis and analysis
We defined objective response rate as the proportion of participants with partial or complete
response as defined by authors of the included studies; for hematological malignancies, we
considered any of the various methods of measuring response (e.g., cytogenetic, molecular, or
flow criteria) as acceptable. For acute leukemias, we did not count partial responses in our
assessment of objective response, since anything short of complete response is not considered
a benefit for these malignancies. Toxicity and adverse events (AEs) (grade 3, 4, or 5 drug-
related events) were measured as defined by the Common Toxicity Criteria version 2.0 and
revised versions (Common Terminology Criteria for Adverse Events version 3.0 and version
4.0).
Risk and benefit for pediatric Phase 1 Trials in oncology
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Because large differences were observed in response rate between solid tumors and hemato-
logical malignancies, our meta-analysis was also stratified by type of cancer. For 9 studies that
included both solid tumors and hematological malignancies, patients were separated for
response analysis.
Pooled response rate and fatal (grade 5) AE rate were calculated within each stratum when
more than 1 study provided data using meta-analytic methods. Modeling with random effects
and the restricted maximum likelihood (REML) estimator was used to account for between-
study heterogeneity. I2 statistics were calculated to provide a measure of the proportion of
overall variation attributable to between-study heterogeneity. Differences in response rate and
grade 5 AE rate between categories of type of therapy, number of drugs, and number of types
of malignancies were assessed using the Q test for heterogeneity in meta-regression. Pooled
response and grade 5 AE rate were calculated for categories of publication year (2004–2006,
2007–2009, 2010–2012, and 2013–2015) to assess changes over time. p-Values for trend in
response and grade 5 AE rate between 2004 and 2015 were obtained from meta-regression.
Meta-analysis was conducted using the metafor package (R version 3.2.3); p< 0.05 was consid-
ered statistically significant.
The average number of grade 3/4 AEs per person with 95% confidence interval was esti-
mated using a Poisson regression model. In cases where a fatal event was not clearly described
as treatment-related, we excluded it from our estimations of grade 5 AE rate. In order to com-
pare risk and benefits, we analyzed a cohort of studies where both drug-related deaths (grade 5
AEs) and response were clearly reported.
Results
Characteristics of the trials
Our search identified a total of 7,061 citations for review. A total of 170 unique studies met full
eligibility for extraction. Our sample included 74 studies of targeted drugs (43.53%), 72 studies
testing classic chemotherapy (42.35%), and 24 studies testing a combination of the two (com-
bined therapy) (14.12%). A full list of drugs tested is shown in S3 Table.
Table 1 summarizes the characteristics of the studies in our sample. The vast majority
reported Phase I trials only (155 trials, 91.18%), and 15 studies reported the results of Phase I
and Phase II trials (8.82%). According to references provided by the authors, most of the pedi-
atric studies were initiated following completion of the corresponding studies in adults (111
studies, 65.29% of all trials). However, 57 studies (33.53%) did not report adult studies as hav-
ing been completed. One hundred twenty-eight studies (75.29%) included only patients with
solid tumors, and 33 only with hematological malignancies (19.41%). The vast majority of
the studies, 144 (84.71%), used conservative dosing strategies, where the initial dose increase
was<100%; 4 (2.35%) trials used aggressive dosing designs, where at least the first 2 doses
increased by 100%; and another 4 trials used a “modified Fibonacci” dosing strategy (defined
as a dose increased by 100% then 66% and 50%). The majority of the studies (74.12%) recom-
mended Phase II trials, and 6 (3.53%) recommended against further testing. The majority of
corresponding authors were affiliated with North American institutions (81.18%).
Characteristics of the patients
Baseline characteristics of the 4,604 enrolled patients are provided in Table 2. In 139 studies
the median age of participants was below 21 years, and in the remaining 31 studies median age
was not reported. In all studies included, pediatric participants were the majority. Patients’
performance status at baseline was difficult to assess as only 32 studies reported these data, and
Risk and benefit for pediatric Phase 1 Trials in oncology
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the studies used 3 different scales, depending on the age of enrolled patients (Karnofsky,
Lansky, or WHO/Zubrod scale).
Surrogate clinical benefit
We defined objective response as the surrogate clinical benefit because objective response—
the main read-out of treatment response used in Phase I trials—does not always predict
Table 1. Characteristics of studies.
Characteristic Category Type of therapy Total
Chemotherapy Targeted therapy Combined therapy
All studies 72 (42.35) 74 (43.53) 24 (14.12) 170 (100)
Study definition Phase I 66 (91.67) 67 (90.54) 22 (91.67) 155 (91.18)
Phase I/II 6 (8.33) 7 (9.46) 2 (8.33) 15 (8.82)
Type of tumor Solid tumor 55 (76.39) 56 (75.68) 17 (70.83) 128 (75.29)
Hematological 13 (18.06) 13 (17.57) 7 (29.17) 33 (19.41)
Both 4 (5.56) 5 (6.76) 0 (0) 9 (5.29)
Number of types of malignancies 1 type 8 (11.11) 11 (14.86) 2 (8.33) 21 (12.35)
2 or 3 types 13 (18.06) 9 (12.16) 3 (12.50) 25 (14.71)
4 types 5 (6.94) 6 (8.11) 1 (4.17) 12 (7.06)
More than 4 45 (62.50) 46 (62.16) 16 (66.67) 107 (62.94)
Not reported 1 (1.39) 2 (2.70) 2 (8.33) 5 (2.94)
Initiated after study in adults Ongoing study in adults 0 (0) 1 (1.35) 0 (0) 1 (0.59)
After adult Phase I 50 (69.44) 52 (70.27) 9 (37.50) 111 (65.29)
Unclear 4 (5.56) 6 (8.11) 6 (25.00) 16 (9.41)
Not reported 17 (23.61) 14 (18.92) 9 (37.50) 40 (23.53)
No study in adults 1 (1.39) 1 (1.35) 0 (0) 2 (1.18)
Dosing strategy Aggressive 0 (0) 4 (5.41) 0 (0) 4 (2.35)
Conservative 71 (98.61) 56 (75.68) 17 (70.83) 144 (84.71)
Modified Fibonacci 0 (0) 3 (4.05) 1 (4.17) 4 (2.35)
Unclear 1 (1.39) 11 (14.86) 4 (16.67) 16 (9.41)
Not reported 0 (0) 0 (0) 2 (8.33) 2 (1.18)
Phase II was recommended Yes 62 (86.11) 47 (63.51) 17 (70.83) 126 (74.12)
No 4 (5.56) 2 (2.70) 0 (0) 6 (3.53)
Unclear or not reported 6 (8.33) 25 (33.78) 7 (29.17) 38 (22.35)
Number of drugs 1 drug 33 (45.83) 68 (91.89) 0 (0) 101 (59.41)
2 or more drugs 39 (54.17) 6 (8.11) 24 (100) 69 (40.59)
Funding Private for profit 5 (6.94) 4 (5.41) 1 (4.17) 10 (5.88)
Private not for profit 2 (2.78) 0 (0) 1 (4.17) 3 (1.76)
Public 15 (20.83) 25 (33.78) 6 (25.00) 46 (27.06)
Mixed 34 (47.22) 28 (37.84) 10 (41.67) 72 (42.35)
Not funded 1 (1.39) 0 (0) 0 (0) 1 (0.59)
Not reported 15 (20.83) 16 (22.97) 6 (25.00) 38 (22.35)
Affiliation of the corresponding author Australia 1 (1.39) 2 (2.70) 0 (0) 3 (1.76)
North America 56 (77.78) 60 (81.08) 22 (91.67) 138 (81.18)
Europe 10 (13.89) 11 (14.86) 0 (0) 21 (12.35)
Asia 0 (0) 0 (0) 1 (4.17) 1 (0.59)
Not reported 5 (6.94) 1 (1.35) 1 (4.17) 7 (4.12)
Data given as number of studies (percent).
https://doi.org/10.1371/journal.pmed.1002505.t001
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improved survival. Objective response rates were reported in 167 of the 170 trials. There were
406 objective responses reported among 4,349 patients enrolled in the 167 trials (Table 3). The
pooled overall response rate across all malignancies was 10.29% (95% CI 8.33% to 12.25%;
I2 = 74.49%; Tau2 [estimate of between-study variance] = 0.0007). The response rate for solid
tumors among 3,569 patients was 3.17% (95% CI 2.62% to 3.72%), while the response rate for
hematological malignancies among 780 patients was significantly higher: 27.90% (95% CI
20.53% to 35.27%); p< 0.001. Response rates varied according to the type of therapy used,
significantly so in solid tumors (p = 0.0045), while in case of hematological malignancies this
relation was at the limit of statistical significance (p = 0.1047). Higher response rates were
observed in combined therapy trials: 44.12% (95% CI 26.30% to 61.94%) for hematological
malignancies and 6.44% (95% CI 3.82% to 9.05%) for solid tumors. Response rates were simi-
lar for solid tumors tested with classical chemotherapy (6.39%; 95% CI 4.60% to 8.17%) and
combined therapy (6.44%; 3.82% to 9.05%).
We also found significant differences in response rate related to the number of drugs used
per study, regardless of the type of therapy (S4 Table). The response rate was higher in all stud-
ies where 2 or more drugs were tested in comparison to single-drug studies (Tables 1 and S3).
The highest relative difference between response rates was identified in solid tumors. For
cancers treated with 1 drug, the response rate was 2.49% (95% CI 1.88% to 3.11%), while for
cancers treated with 2 or more drugs, it was 10.54% (95% CI 7.61% to 13.46%); p< 0.001.
Another significant difference between responses was related to the number of types of malig-
nancies included in a study. The response rate was much higher in all interventions where 3 or
fewer types of cancers were treated in comparison to the studies with 4 or more types of malig-
nancies. The highest relative difference between responses was again identified in solid tumors.
When 3 or fewer types of malignancies were included in a study, response rate was 15.01%
(95% CI 6.70% to 23.32%). When 4 or more different malignancies were included in a study,
response rate was 2.85% (95% CI 2.28% to 3.42%); p< 0.001.
We did not find significant linear time trends in objective response rates (p = 0.25 for solid
tumors, p = 0.64 for hematological malignancies) (Fig 1). Table 3 shows details of response
rates and fatal (grade 5) AE rates in different therapy subgroups.
Table 2. Characteristics of patients.
Characteristic Category Type of therapy
Chemotherapy Targeted therapy Combined therapy All interventions
Enrolled patients, n 1,757 2,264 583 4,604
Evaluated patients, n (%) 1,615 (91.92) 2,028 (89.58) 543 (93.14) 4,186 (90.92)
Male, n (%) 844 (48.04) 997 (44.04) 291 (49.91) 2,132 (46.31)
Median age of participants, n of studies <7 years 2 3 0 5
7.0–13.9 years 51 47 15 113
14.0–20.9 years 6 13 2 21
21 years 0 0 0 0
Not reported as median 13 11 7 31
Mean percentage of patients receiving dose Below recommended 35.4 35.7 28.3 39.1
Recommended 33.8 40.4 44.4 32.2
Gender was not reported in 12 chemotherapy, 17 targeted therapy, and 4 combination therapy studies.
Calculated as a mean of percentage of patients given recommended dose or dose below recommended dose in individual studies, weighted by the size of the study (if
such data were reported).
https://doi.org/10.1371/journal.pmed.1002505.t002
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Adverse events
A total of 70 of the 170 trials reported fatal (grade 5) AEs. We observed 37 grade 5 AEs clearly
reported among 1,838 patients (Table 3), suggesting an overall grade 5 AE rate of 2.09% (95%
CI 1.45% to 2.72%; I2 = 0.0%; Tau2 = 0). This included 14 patients with solid tumors (1.85%;
95% CI 1.14% to 2.56%) and 23 patients with hematological malignancies (4.04%; 95% CI
2.18% to 5.89%). Differences in AE rates by type of therapy were not statistically significant.
Grade 3/4 AEs were reported in 129 studies among 3,547 patients, with an average rate per
person of 1.32 (95% CI 1.28 to 1.36). This included on average 1.34 (95% CI 1.22 to 1.47) grade
3/4 AEs per person with solid tumors and 1.22 (95% CI 1.12 to 1.31) grade 3/4 AEs per person
with hematological malignancies. The highest average grade 3/4 AE rate per person was identi-
fied in patients with hematological malignancies tested with combined therapies: 2.75 (95% CI
2.46 to 3.07). We did not find significant linear time trends in fatal (grade 5) AEs (p = 0.9 for
solid, p = 0.7 for hematological) (Fig 1). However, there was a significant difference in grade 5
AE rate (p = 0.02) for hematological malignancies between 2004–2006 (1.03%; 95% CI 0.10%
to 2.87%) and 2007–2009 (7.79%; 95% CI 2.52% to 13.06%).
Table 3. Comparison of objective response rate and toxicity in therapy subgroups by type of malignancy.
Outcome Type of malignancy Measure Type of therapy
Chemotherapy Targeted
therapy
Combined
therapy
All
interventions
Objective responses (167
studies)
Solid tumors Number of studies 56 58 15 129
Response rate (95% CI) 6.39%
(4.60–8.17)
2.52%
(1.82–3.22)
6.44%
(3.82–9.05)
3.17%
(2.62–3.72)
p-Value 0.0045 —
Hematological
malignancies
Number of studies 15 16 7 38
Response rate (95% CI) 26.18%
(15.17–37.18)
22.80%
(11.51–34.08)
44.12%
(26.30–61.94)
27.90%
(20.53–35.27)
p-Value 0.1047 <0.001
Fatal (grade 5) AEs (70
studies)
Solid tumors Number of studies 18 27 2 47
Grade 5 AE rate (95% CI) 1.09%
(0.15–2.03)
1.70%
(0.82–2.59)
1.68%
(0.10–4.32)
1.85%
(1.14–2.56)
p-Value 0.835 -
Hematological
malignancies
Number of studies 10 9 4 23
Grade 5 AE rate (95% CI) 3.70%
(1.01–6.39)
3.16%
(0.69–5.63)
6.33%
(1.15–11.51)
4.04%
(2.18–5.89)
p-Value 0.28 0.14
Grade 3/4 AEs (129
studies)
Solid tumors Number of studies 41 51 11 103
Mean number of grade 3/4 AEs per
person (95% CI)
2.01
(1.93–2.10)
0.79
(0.74–0.85)
1.76
(1.61–1.93)
1.34
(1.22–1.47)
p-Value <0.001 —
Hematological
malignancies
Number of studies 11 9 6 26
Mean number of grade 3/4 AEs per
person (95% CI)
0.98
(0.87–1.10)
0.75
(0.65–0.87)
2.75
(2.46–3.07)
1.22
(1.12–1.31)
p-Value <0.001 0.01
p-Value from Q test for heterogeneity comparing response rate and grade 5 AE rate between type-of-therapy groups.
p-Value from Q test for heterogeneity comparing response rate and grade 5 AE rate between types of tumor.
p-Value from Poisson regression.
AE, adverse event.
https://doi.org/10.1371/journal.pmed.1002505.t003
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Direct comparison of risk and benefit
For direct risk and benefit evaluation, we identified a cohort of 66 studies out of the 170 where
both objective responses and grade 5 AEs were reported (S5 Table). For sensitivity analysis, we
Fig 1. Time trends in response and treatment-related toxicity. Response and fatal (grade 5) adverse event (AE) rates were calculated for
categories of publication year (2004–2006, 2007–2009, 2010–2012, and 2013–2015) to assess changes over time. Error bars indicate standard
error.
https://doi.org/10.1371/journal.pmed.1002505.g001
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calculated response rates in the subgroup of 66 studies and compared them with response
rates in the rest of the 101 studies where objective responses were reported. There were no sta-
tistical differences between these 2 groups in the case of solid tumors (2.97% versus 3.31%,
p = 0.54) and hematological tumors (26.74% versus 29.42%, p = 0.81). We also calculated the
grade 5 AE rates in the subgroup of 66 studies, and the majority of the results were almost
identical as in the 70 studies where grade 5 AEs were reported. We found that higher response
rates were associated with higher grade 5 AE rates in hematological malignancies. We did not
find this relationship in solid tumors.
Discussion
Our findings suggest that, on average, 1 in 10 children who enroll in pediatric Phase I trials
experience objective response, while 1 in 50 die from drug-related AEs.
Because pediatric Phase I cancer trials enroll populations that lack competence to provide
informed consent, these trials are generally pursued in a manner that maximizes their thera-
peutic prospect and reduces their risk. For example, they are generally pursued only after adult
trials have clarified toxicity and appropriate dosing, and they generally test a narrower dose
range. Despite this, our findings suggest that pediatric Phase I studies have similar drug-related
serious (grade 3, 4, and 5) AE and response rates as adult studies. In S6 Table we compare our
results with 6 similar reviews of adult Phase I cancer trials and 1 review of trials in pediatric
populations. Despite the differences in methods applied in these studies, the pooled overall
response rate for all types of cancers (solid and hematological) in our study was similar to that
presented in meta-research with adults (10.6%) [38] and much higher than that in another
study (2.95%) [39]. The pediatric response rate in our study for solid tumors, 3.17% (95% CI
2.62% to 3.72%), was slightly lower than that in adult solid tumor trials (3.8%) [40] and much
lower than results presented in a smaller study (7.2%) [41]. We should further note that our
aggregate objective response estimate for pediatric studies does not appear to have been driven
by a small number of Phase I trials with large dose expansion cohorts. Only 44 trials involved
dose expansion cohorts. Response rates for these trials did not differ from those not having
dose expansion cohorts (p = 0.10), nor did we observe an obvious relationship between higher
response rate and higher number of patients in expansion cohorts (Spearman’s rank correla-
tion coefficient R = −0.08, p = 0.7; see S2 Fig).
The overall death rate calculated in our systematic review was also higher in comparison
with non-pediatric trials, though the size of the difference may be caused by differences in the
calculation method [38,40] (S6 Table). Despite an evolution in new treatments and study
methods, we did not find linear time trends in risk and benefit across the time period of our
analysis.
The number of patients receiving doses recommended for subsequent testing can be
interpreted as another proxy of therapeutic value for Phase I trials [38], though it should be
noted that, on the one hand, a minority of drugs completing Phase I studies are ultimately
proven safe and effective, while, on the other hand, doses lower than those recommended can
still be therapeutic (if suboptimal). Overall, 32% of the patients received the recommended
dose and 39% received doses below that recommended (weighted mean). Designs intended
to increase the number of patients receiving the recommended dose [2,28,42–45] were
uncommon.
We found a significantly higher overall response rate in hematological malignancies than in
solid tumors. This likely reflects different criteria used to assess response, differences in the
biology of these malignancies, and that the former typically enroll a more homogeneous set of
indications. The response rate was also higher in all interventions where 2 or more drugs were
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tested in comparison to the single-drug studies. The response rate was higher in all interven-
tions where 3 or fewer types of malignancies were treated in comparison to the studies with 4
or more malignancies. This possibly indicates that studies where patients with a wider variety
of malignancies are enrolled are based on a weaker research hypothesis regarding the efficacy
of the tested agent against the specific malignancy. The average grade 3/4 AE rate per person
was 1.32, which means that the typical patient was exposed to at least 1 major side effect of a
therapy.
Our findings should be interpreted in light of the following limitations. First, the trials ana-
lyzed in our review were very heterogeneous. We used broad inclusion criteria to summarize
the global response rate and risk. To reduce heterogeneity, we separated therapy types (chemo-
therapy, targeted agents, and combined therapies) and cancer types (solid tumors and hemato-
logical malignancies). We also explored this heterogeneity using meta-regression. Second, we
relied only on published data and on the quality of reporting. Many current studies illustrate
discrepancies between clinical trial registry records and published articles [46–49]. Moreover,
we identified serious issues with reporting in our set of 170 analyzed trials. For instance, the
poor quality of outcome reporting did not allow us to meta-analyze grade 3/4 AEs, and we
were able to pool only the average number of grade 3/4 AEs per patient. Third, there was no
explicit information about treatment-related deaths (grade 5 AEs) in 58.82% of studies—a fig-
ure that is surprising given the goal of Phase I trials. The low number of clearly reported treat-
ment-related grade 5 AEs is an important limitation of our data synthesis. Fourth, response
rates were used as a surrogate for benefit in our study. On the one hand, response rates could
be a sensitive measure of benefit in the context of pediatric malignancies, given their rapid pro-
gression. On the other hand, the relationship between response rates and patient-centered out-
comes like quality of life or survival is variable [33–37]. Moreover, eventual drug approvals are
usually based on survival data from randomized controlled trials, and only about 6.7% to 9.6%
of drugs tested in oncology will eventually be registered [50,51]. Better measures of benefit,
like progression-free or overall survival, are typically not available in Phase I trials. Our mea-
sure of safety did not consider potential downstream effects, like secondary malignancies.
In adult Phase I cancer research, there is a lively debate as to whether access to treatments
through trials is therapeutic [6–9,11,24,52]. This debate has particular significance for pediatric
trials, since national and international policies generally require that interventions in trials pre-
senting greater than minor increase over minimal risk must “hold out the prospect of direct
benefit for the individual subject” and that “the relation of the anticipated benefit to the risk is
at least as favorable to the subjects as that presented by available alternative approaches” [53].
Although experimental treatments in Phase I studies that deliver active drug doses clearly
meet the first condition, the favorability of risk against benefit in comparison with alternative
treatment options is subject to interpretation and may vary depending on the trial. Our data,
coupled with careful ethical analysis, provide an empirical basis for further discussions about
the therapeutic status of Phase I trials in children. In particular, they provide evidence for
refining risk/benefit balance in Phase I trials and identifying those studies that present greater
challenges for meeting standards of acceptable risk in children. They also provide a basis for
clearer communications about risk and benefit to patients and their guardians.
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